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Context:Over 23 million Americans are afflicted with severe obesity, i.e. their body mass index (in
kilograms per square meter) values exceed 35. Of even greater concern is the association of the
adiposity with comorbidities such as diabetes, hypertension, cardiopulmonary failure, asthma,
pseudotumor cerebri, infertility, and crippling arthritis.
Objective:Diets, exercise, behavioralmodification, anddrugs arenot effective in these individuals.
This article examines the effect of surgery on the control of the weight and the comorbidities, as
well as the safety of these operations.
Interventions: Although the article focuses on the outcomes of the three most commonly per-
formed operations, i.e. adjustable gastric banding, the gastric bypass, and the biliopancreatic
bypass with duodenal switch, it aims for perspective with the inclusion of abandoned and current
investigational procedures, a review of the complications, and an emphasis on the appropriate
selection of patients.
Positions:Ample evidence, including controlled randomized studies, nowdocument that bariatric
surgery produces durableweight loss exceeding100 lb (46 kg), full and long-term remissionof type
2 diabetes in over 80% with salutary effects on the other comorbidities as well with significant
reductions in all-cause mortality. Although the severely obese present with serious surgical risks,
bariatric surgery is performed safely with a 0.35%90-dmortality in Centers of Excellence through-
out the United States—similar to the complication rates after cholecystectomy.
Conclusions: Until better approaches become available, bariatric surgery is the therapy of choice
for patients with severe obesity. (J Clin Endocrinol Metab 93: S89–S96, 2008)
Pretty hard to believe. How can it be that one operation canproduce full and durable remissions of our most resistant
chronic diseases? How can one procedure reverse obesity,
diabetes, hypertension, cardiopulmonary failure, polycystic
ovary disease, and pseudotumor cerebri with a reduction in
mortality (Fig. 1)? And, finally, is it really true that the op-
eration, a highly complex abdominal procedure performed in
vulnerable, severely obese patients, is now delivered through-
out the United States with operative mortalities and morbid-
ities that are no greater than the risks for cholecystectomy?
Surprisingly, these claims are well supported.
The intent of this article is to review the history of bariatric
surgery, to compare the various bariatric operations, to list the
current indications for these procedures, to evaluate the out-
comes, and to consider the risks.
The History of Bariatric Surgery
Bariatric surgery, similar to the other surgical disciplines, was
developed in waves through the contributions of many (1). The
first breakthroughwas the recognition by a group of surgeons at
the University of Minnesota, led by Drs. Arnold Kremen and
Richard Varco, that severe obesity was a disease dangerous
enough to warrant surgery. Based on the experience with the
“short gut” syndrome, they developed the intestinal bypass, a
procedure that excludes the majority of the small intestine from
contact with food.Multiple variations finally demonstrated that
an end-to-end anastomosis between 14 inches (36 cm) of jeju-
num and 4 inches (10 cm) of ileum with the excluded segment
draining into the sigmoid colon provided the most predictable
weight loss. It is oneof thedarkblots in thehistoryof surgery that
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over 30,000 intestinal bypass operations were performed before
it was recognized that although the operations produced signif-
icant weight loss, the complications were unacceptable. Eventu-
ally almost all had to be reversed because they produced acute
hepatic failure, cirrhosis, renal failure, autoimmune disease, and
severe mineral abnormalities.
The second major breakthrough came with the careful inves-
tigations byDr. EdwardMason, also amember of theMinnesota
group, who documented that weight loss could be achieved as
effectively and far more safely through two gastric procedures,
the gastric band, an operation that limited intake with a small
gastric pouch and limited outlet, and the gastric bypass, a pro-
cedure that interfered with digestion as well as intake by exclud-
ing food from the stomach. These two basic operations continue
to be the most widely performed bariatric procedures in the
world today. Gastric banding has been improved with the in-
vention of the adjustable gastric band; the gastric bypass was
extended by Scopinaro et al. (2) with the biliopancreatic bypass
and by Hess et al. (3) with the addition of a duodenal switch.
More recently, the gastric sleeve (GS) (4), the initial step in the
biliopancreatic bypass, is under investigation as another inde-
pendent restrictive operation.Moo andRubino (5), interested in
extending the benefits of the gastric bypass to diabetic patients
who are not obese, have stimulated trials of the duodeno-jejunal
bypass. Others are testing ileal transposition, i.e. the translocation
of a segment of ileum close to the Ligament of Treitz, as another
approach to resolving type 2 diabetes without weight loss.
The third advance was the documentation by Pories et al. (6)
and MacDonald et al. (7), with rigorous 95% follow-up of
608 patients for up to 16 yr, that the gastric bypass produced
1) durableweight loss greater than 100 lb; 2) control of the comor-
bidities, even including diabetes; and 3) a decrease in mortality.
The fourth major development was the demonstration in
1994 by Wittgrove and Clark (8) that the gastric bypass, one of
the most difficult abdominal surgical operations, could be per-
formed with the laparoscopic approach
safely and with far less trauma.
The fifth singular innovationwas quality
control of bariatric surgery on a nationwide
basis and the documentation that the oper-
ations couldbedonewithminimalmortality
and morbidity in centers with high volume
and experience. Confronted by reports of
disastrous clinical outcomes in hospitals
with limited experience, an explosion of
malpractice suits and unaffordable insur-
ance premiums, the leadership of the Amer-
icanSociety forBariatric andMetabolic Sur-
gery (ASMBS) founded a program for the
certification of Centers of Excellence. The
concept differed from previous attempts at
surgical quality control by requiring stan-
dardization of care paths and focusing not
only on process but primarily on surgical
outcomes. To assure credibility and stake-
holder participation, the Society founded
the Surgical Review Corporation (SRC)
(www.surgicalreview.org), an independent, nonprofit organiza-
tion, tomanage theprogram (9).Asof July 1, 2008, a total of 339
hospitals throughout the United States were certified as ASMBS
Centers of Excellence, delivering bariatric surgery with a 0.14%
hospital and a 0.35% 90-d mortality, similar rates to those re-
ported for cholecystectomy, although the severely obese repre-
sent far greater operative risks (10).
Variations on a Theme
Bariatric operations have traditionally been divided into three
groups: 1) restrictive, i.e. procedures that produce weight loss
solely by limiting intake (gastric banding,GS); 2)malabsorptive,
i.e.operations that induceweight loss totallyby interferencewith
digestion and absorption (intestinal bypass); and 3) and mixed,
i.e.procedures that limit intake andproducemalabsorption (gas-
tric bypass, duodenal switch). Despite this apparently clear clas-
sification, the mechanisms of action remain unclear. For exam-
ple,whereas theGS is considered a restrictive procedure, limiting
intake due to the low volume of the tube, the longitudinal gas-
trectomy also discards the source of ghrelin production.
Figure 2 provides a diagrammatic overview of the various
operations previously or currently in use. The list is only partial.
Multiple variations of each of the operations have been per-
formed and discarded over the last 50 yr with variations in the
size of the gastric pouches, length of limbs, type and size of
anastomoses, with or without vagotomy, the addition of con-
stricting rings, and even wrapping the entire stomach in fabric.
Operations No Longer Widely Performed
A listing of the operations that were once popular and are now
no longer performed is important because patients with these
procedures are still encountered in practice.
FIG. 1. Gastric bypass surgery schedule. Dx, Diognosis; OR, operating room.
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Intestinal bypass
Thisoriginalbariatric surgical procedure excludesmostof the
small bowel by joining 14 in. (36 cm) of proximal jejunum be-
yond the Ligament of Treitz to 4 in. (10 cm) of terminal ileum.
The excluded segment is drained into the distal colon (11). The
disastrous outcomes of these procedures are noted in the
introduction.
Vertical banded gastroplasty (VBG)
The VBG was the first successful restrictive procedure. The
operation produced a 30-cc proximal gastric pouch with a ver-
tical staple line from the Angle of His to a circular opening,
measuring about 1 cm, punched out with a circular stapler. This
opening provided the passage for a plastic band, usuallymade of
Marlex, about 1 cm in width, that was tightened to narrow the
outlet to about 1 cm. The operation is still performed by a few
surgeons with excellent results but has been largely replaced
by the adjustable gastric band, an operation that is far easier
to perform, safer, and less likely to fail due to staple line
breakdown.
Minigastric loop bypass
Theminigastric loopbypasswas the first versionof the gastric
bypass, but it was soon abandoned because of biliary regurgi-
tation with bile gastritis and esophagitis. In
addition, animal studies documenting dys-
plasia raised concerns about potential dan-
gers of esophageal cancer. Although the op-
eration is avoided by most, a few surgeons
insist the procedure is safe and continue to
promote it (12).
Currently Accepted Operations
Roux-en-Y gastric bypass (RYGB)
The RYGB, the most commonly per-
formed bariatric operation in the United
States, creates a proximal pouch about 30 cc
in size, i.e. about the size of a golf ball, by
segmentation of the stomachwith staples or
division. The proximal pouch is drained
with a Roux-en-Y created by dividing the
proximal jejunum about 30 cm below the
Ligament of Treitz, bringing the distal seg-
ment up to form a gastroenterostomy of
about 1 cm in diameter, and joining the
proximal segment to the small bowel about
100 cm below the point of division. Al-
though the procedure is becoming increas-
ingly standardized, variations continuewith
differences in the size of the gastric pouches,
constructionof the gastrojejunostomies, use
of a plastic ring at the gastroenterostomy to
limit outflow, length of the Roux-en-Y
limbs, and placement of the small bowel in
front or behind the colon (13).
Adjustable gastric band (AGB)
TheAGBhas rapidly gained in popularity in theUnited States
and abroaddue to its safety and effectiveness. TheAGB is a small
bracelet-like device placed high in the stomach to produce a
pouch of about 30 cm, similar to that in the RYGB. The band is
lined by an inflatable cuff that is joined to a sc abdominal port to
allow adjustment of the pouch outflow (14).
Biliopancreatic bypass with duodenal switch (BPDS)
TheBPDS reduces the gastric reservoir by excisingmost of the
stomach, leavingonly a“gastric sleeve.”Theduodenum,divided
about 2 cm below the pylorus, is reconstituted by a Roux-en- Y
anastomosis to the distal jejunum, excluding significantly more
small bowel than the gastric bypass. The operation is not widely
performed but is gaining adherents due to its effectiveness and
the ease of creating the GS, which appears to offer a reasonable
alternative to the gastric band (13).
Investigational Bariatric Surgical Procedures
Gastric sleeve (GS)
The GS creates a narrow gastric tube through the excision of
most of the stomach. The operation does more than just limit
FIG. 2. Overview of bariatric and metabolic surgical operations.
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intake; it also removes most and perhaps all of the ghrelin-pro-
ducing cells of the gastric mucosa. The procedure, initially in-
troduced as a first stage of the BPDS for use in superobese pa-
tients to reduce risk, appears to be an effective operation on its
ownand apotential competitorwith theAGB.The early data are
encouraging; somemaintain that this operation shouldno longer
be listed as investigational because of the excellent results re-
ported (15).
Duodeno-jejunal bypass
The duodeno-jejunal bypass stomach-sparing operation was
introduced as a procedure that could induce remission of dia-
betes without weight loss in lean patients with type 2 diabetes
mellitus. The operation is based on the work of Rubino and
colleagues (16) in Goto-Kakizaki genetically diabetic lean rats.
Early human trials are encouraging.
Ileal transposition
Ileal transposition is still in the early stage of animal and
human trials. It is mentioned here for completeness and to make
the reader aware that there are early reports of satisfactory
weight loss and remission of diabetes, but the evidence remains
scant at this point, even in animal trials (17).
Effect of Bariatric Surgery on Weight
Bariatric surgery, themost effective treatment for severe obesity,
produces dramatic and durable weight loss. Weight loss is most
easily expressed in pounds or kilograms. In our series of 608
patients followed up to 16 yr with a 95% follow-up, the mean
weight loss was 106 lb (48.2 kg.) decreasing from 317 to 211 lb
(144.1 to 95.9 kg) (18).
Because of gender differences aswell as the great variations in
weight among the operated individuals, many prefer to express
weight loss in terms of “excess weight,” i.e. current weight 
ideal bodyweight excessweight. For example, according to the
Metropolitan Life Insurance tables of 1999, a 5-foot 3-in.
woman with a medium frame has an “ideal body weight” of
121–135 lb (55–61 kg). The midpoint of this range is 128 lb
(58.1 kg). At a weight of 300 lb, she has an excess weight of 172
lb (78.2 kg). If herweight after a gastric bypass is 180 lb (81.8 kg)
upon stabilization, usually at about 18months after surgery, she
lost 120 lb (54.5 kg) or 69.7% of her excess body weight.
The use of percentage excess weight loss as a measure allows
some comparison between the various bariatric operations.
Buchwald et al. (19) used this metric in a meta-analysis of 2,738
citations in the English language from1990–2002 that reviewed
the results of bariatric surgery in 22,094 patients. These data
showed the following outcomes, expressed in excess weight loss:
AGB, 47.5%; VBG, 68.2%; RYGB, 61.6%; and BPDS, 79.1%.
Although these figures are helpful and reasonably accurate, they
reflect the outcomes of a rapidly changing technology, including
improved stapling devices and bands that are less likely to fail as
well as a sharp move from open to laparoscopic procedures.
The bodymass index (BMI; in kilograms per square meter) is
also frequently used as an index of obesity. However, although
the BMI has been adopted widely, it is a badly flawed index for
several reasons. As a unigender measure, it fails to reflect the
differences in muscularity and body composition between the
sexes. Because it only reflects weight and height, it fails to dif-
ferentiate between the well-muscled athlete and the obese indi-
vidual.Oneofourbest runningbacks atEastCarolinaUniversity
had a BMI of 46.8, based on his height of 5-ft 8-in. (173 cm) and
weight of 308 lb (140 kg), numbers that do not reflect the fact
that his body fat represented only 7% of his body weight. The
BMImeasure is also unfavorable to some racial groups (20).Due
to racial differences in body composition, African-American and
Asian women suffer similar levels of comorbidities at a BMI of
32 that theirCaucasian sisters encounter at aBMIof 35.Therefore,
when the BMI of at least 35 is used as an exclusion index, it denies
access to someof the populationwith the greatest need for bariatric
surgery. Similarly, it can be argued that some patients currently
undergo surgery based on their BMI, but possibly with a body fat
percentage close to normal range. It is not a sufficiently precise
measure on which to base life and death decisions.
Patients vary in their responses to bariatric operations. Most
patients change their diets (21) with a tendency to avoid beef
products and fibrous vegetables because they require a lot of
chewing and may obstruct the narrow gastric outflow tracts.
Some patients develop the symptoms of “dumping” when they
eat sweets. Some learn tominimize or avoid alcohol because they
get drunk much more easily; whereas still others report major
changes in taste and food preference.
Other factors that influence weight loss include age, gen-
der, race, body composition, education, emotional status, and
level of activity (13). In general, younger patients, females,
Caucasians, muscular and highly motivated individuals who
follow an exercise program, patients who return for scheduled
follow-up, and those who comply with the recommendations
for vitamin/mineral supplements and do not snack will lose
the most weight.
The surgical approach, i.e.“open” throughamidlineabdominal
incisionvs.“closed”witha laparoscopicapproach,doesnotseemto
affect the degree of weight loss (22, 23), although the recovery is
significantly faster after minimally invasive approaches.
Most patients reach their maximum weight loss by 2 yr and
experience some increase of weight, perhaps 5–7%, by the fifth
year with a gradual decrease again over the following years.
Weight loss after the insertion of adjustable bands is generally
less and slower thanafter gastricbypass and theduodenal switch,
although there is early evidence that weight loss after banding
may continue into the fifth year.
Failure of bariatric surgery remains to be defined. Failure,
measured by the inadequate loss or the return of lost weight,
varies by procedure and intensity of follow-up, ranging between
5 and 10% with higher rates for adjustable gastric banding.
However, the lack of improvement of the comorbidities such as
diabetes, asthma, stress incontinence, infertility, cardiopulmo-
nary function, and pseudotumor represent more serious failures
than inadequate weight loss. The developing large databases in
the National Institutes of Health (NIH) Longitudinal Assess-
ment of Bariatric Surgery (LABS) and the certification of Centers
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of Excellence for Bariatric Surgery should provide the informa-
tion to develop objective measures.
If the weight gain is due to a technical failure of the operation
from such factors as staple line breakdown, revisional surgery is
usually successful. If, on the other hand, the failure is due to
behavioral problems such as patients “out-eating” the opera-
tion, revision is usually not an effective approach.
Effect of Bariatric Surgery on Diabetes
The most remarkable effect of bariatric surgery is the full and
rapid remission of type 2 diabetes mellitus, a disease previously
considered unalterably progressive and minimally unresponsive
to therapies except with a few demanding and unrealistic pro-
tocols. Despite the variousmedical advances, diabetes continues
to be our most expensive disease. Diabetes, increasing at a faster
rate than any other chronic disease, now affects over 24 million
Americans and represents themain cause of blindness, renal fail-
ure, andamputations in theUnited States aswell as amajor cause
of heart disease and stroke. The disease accounts for 11–13% of
all health care expenseswithan estimatedannual cost of $73,000
per year for the recommendedmanagement of afflicted patients.
Diabetes clears in four out of five patients. Table 1 documents
the long-term outcomes in a series of 608 severely obese indi-
viduals treatedwith thegastricbypass.Of these, 165patientshad
type 2 diabetes and another 165 patients had impaired glucose
tolerance (IGT). Durable resolution of diabetes with a return to
euglycemia and normalization of glycosylated hemoglobin val-
ues occurred in 83%of the diabetic and99%of the IGTpatients.
The diabetes clears rapidly, generally in a matter of days, to the
degree that most diabetic bariatric surgical patients are dis-
charged without any antidiabetic medications.
One paper indicates that the gastric bypass also reduces the
mortality fromdiabetes. Although twomajor series (24, 25) doc-
umented the reduction in mortality after gastric bypass, Mac-
Donald et al. (26) showed that in diabetics the mortality de-
creased from 4.5 to 1% per year, based on a comparison group.
The finding that six different operations on the intestine can
produce euglycemia has opened new avenues for diabetes re-
searchwith a focus on the role of the intestine. Gastric inhibitory
peptide, ghrelin, peptide YY3–36, and glucagon-like peptide-1
are only some of the gut hormones under intense investigation.
In fact, exenatide, an analog of glucagon-like peptide-1, is al-
ready enjoying wide and successful clinical application (27).
In the long run, the hope for diabetes lies in the dissection of
the metabolic pathways uncovered by bariatric surgery and ap-
plying the findings to the development of effective medical ther-
apies. We can’t operate on 24 million Americans.
The Effect of Bariatric Surgery on the Other
Comorbidities of Severe Obesity
Severe obesity affects virtually every system of the body with a
broad expression of serious diseases, including pseudotumor
cerebri, hypertension, diabetes, renal failure, immunoincompe-
tence, asthma, gastroesophageal reflux disease, chronic ob-
structive pulmonary disease, cardiac failure, atherosclerosis,
Pickwickian syndrome, arthritis of the weight bearing joints,
infertility, skin breakdown, and an increased prevalence of
cancers, especially colon, prostate, breast, and ovary.
All of these illnesses respond favorably to bariatric surgery,
often with total and permanent remission. It is not unusual for
patients who are restricted to wheelchairs before surgery to re-
turn to the surgeon 3 months later walking, often without even
a cane. Patients diagnosed with asthma and gastroesophageal
refluxdisease, often related, usually find that they no longer need
the various medications.
Most startling is the reduction in the prevalence of cancer in
patients who have undergone bariatric surgery (28). Is this reduc-
tion, about 80% within 5 yr after the surgery, due to the decrease
in inflammatory cytokines with the reduction of adipocytes? We
can only speculate, but the implications are exciting.
Indications and Contraindications to Bariatric
Surgery
The original indications and contraindications to bariatric sur-
gerywere established in 1991 by theNIHConsensusConference
on the Surgery for Obesity. In 2004, the American Society for
Bariatric Surgery ASBS, recently renamed as the American
Society for Metabolic and Bariatric Surgery (ASMBS) up-
dated that statement with a follow-up Consensus Conference
(29) that reached the following conclusions:
1. Bariatric surgery is the most effective therapy available for
morbid obesity and can result in improvement or complete res-
olution of obesity comorbidities.
2. Types of operative procedures for morbid obesity have in-
creased since 1991 and are continuously evolving. There are
currently four types of procedures that can be used to achieve
sustained weight loss: gastric bypass (standard, long-limb, and
very long-limb Roux), alone or in combination with vertical
banded gastroplasty; laparoscopic adjustable gastric banding;
vertical banded gastroplasty; and biliopancreatic diversion and
duodenal switch.
3. Both open and laparoscopic bariatric operations are effec-
tive therapies for morbid obesity and represent complementary
state-of-the-art procedures.
4. Bariatric surgery candidates should have attempted to lose
weight by nonoperative means, including self-directed dieting,
nutritional counseling, and commercial and hospital-based
TABLE 1. Full and durable remission of type 2 diabetes
mellitus in 608 patients after gastric bypass with a mean
follow-up of 9.4 yr
Type 2 diabetes IGT
Total no. of patients 165 165
No. available for follow-up 146 152
Resolution of diabetes 121 (83%) 150 (99%)
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weight loss programs, but should not be required to have com-
pleted formal nonoperative obesity therapy as a precondition for
the operation.
5. The bariatric surgery patient is best evaluated and subse-
quently cared for by a multidisciplinary team.
6. Bariatric surgery candidates should have a comprehensive
medical evaluation before the operation; evaluation by subspe-
cialists (e.g. cardiologists, psychiatrists, and psychologists) is not
routinely needed but should be available if indicated.
7. Bariatric surgery, performed only by experienced centers,
should be considered in morbidly obese adolescents.
8. Extending bariatric surgery to patients with class I obesity
(BMI, 30–34.9 kg/m2), who have a comorbid condition that can
be cured or markedly improved by substantial and sustained
weight loss, may be warranted and requires additional data and
long-term risk and benefit analyses.
9. Bariatric surgery can be cost effective before the fourth year
of follow-up.
10. Bariatric surgery offers rich opportunities for both basic
and translational patient-oriented research to provide a better
understanding of the factors involved in the regulation of food
intake, pathophysiology of obesity, metabolic and clinical ef-
fects of sustained weight loss, and best treatment options for
obese persons.
In practical terms, most physicians, surgeons, and carriers
consider patients eligible for bariatric surgery if their BMI is
at least 40 or if their BMI of at least 35 is accompanied by such
comorbidities as diabetes, hypertension, arthritis limiting
daily function, and cardiopulmonary failure. In the past, the
age limits ranged from 18 to 65 yr, but recent data show that
teenagers and patients older than 70 yr can benefit from the
surgery with little or no increase in risk. Other inclusion cri-
teria include the patient’s ability to understand the surgery
and the consequences of the treatment, to comply with long-
term follow-up, to agree to maintain vitamin and mineral
supplementation, and to report problems promptly to spe-
cialists familiar with the complications of bariatric surgery.
Contraindications include uncontrolled emotional disorders
and drug or alcohol abuse. A relative contraindication ob-
served by many surgeons is a lack of support or strong dis-
agreement with the surgery by the family.
The choice of the individual procedure is not yet based on
sound data, but many surgeons choose to favor gastric bypass
or the duodenal switch over adjustable gastric banding in
patients with diabetes. The rapidly growing databases of the
NIH project, Longitudinal Assessment of Bariatric Surgery
(LABS) and the Surgical Review Corporation (SRC), the in-
dependent, nonprofit organization that manages the ASMBS
Centers of Excellence program, should soon facilitate these
decisions.
Risks of Bariatric Surgery
Bariatric surgery is remarkably safe, especially given the large
size of the patients aswell as the frequency and seriousness of the
comorbidities. Table 2 reflects the data reported in the applica-
tions of 272 ASMBS centers for certification as Centers of Ex-
cellence (30). The low operativemortality rate, while surprising,
has been confirmed in two other series. It is similar to that re-
ported by the NIH LABS group of six participating national
centers, and it is not far removed from the 30-d mortality rates
extracted inBuchwald’smeta-analysis:ABG,0.1%;VBG,0.1%;
RYGB, 0.5%; and BPDS, 1.1%.
Comparison with mortality rates reported from other com-
monoperationsbrings thesevery lowrates into focus.The review
of mortality by Dimick et al. (31) after common operations in
U.S. hospitals revealed the following data: aortic aneurysm,
3.9%; coronary artery bypass graft, 3.5%, esophagectomy, 9%;
and pancreatectomy, 8.3%. Only hip replacement with its mor-
tality of 0.3% was as safe as bariatric surgery.
There is still no proven explanation for the significantmortality
rates afterdischarge—in fact,morepatientsdie afterdischarge than
duringhospitalization.Pulmonary emboli andarrhythmiasare sus-
pected but not yet proven. This is an important issue because these
deaths may be preventable with the appropriate medication.
Although the mortality rates are low, probably due to the
standardizationofbariatric surgical care, the complications after
bariatric surgery can be deadly and must be treated promptly by
surgeons familiar with these problems. The complications fall
into two groups: acute and long-term. The acute complications,
which occur in 5–10% of the patients depending on the proce-
dure, patient risk, age, and condition, mirror those after other
abdominal operations, i.e. hemorrhage, obstruction, anasto-
motic leaks, infection, arrhythmias, and pulmonary emboli. Due
to the patients’weight, rhabdomyolysis is also seen occasionally,
especially after prolonged operations.
Long-term complications may be baffling to those unfa-
miliar with bariatric surgery: neuropathies due to nutritional
deficiencies, internal hernias, anastomotic stenoses, and emo-
tional disorders. Although the nutritional deficits can be
avoided with daily chewable multivitamin and mineral sup-
plements and with calcium and iron for menstruating women,
compliance with this recommendation is not universal. Un-
fortunately, we have seen full-blown cases of beri-beri, pel-
lagra, kwashiorkor and severe neuropathies in patients who
were treated for a variety of rare illnesses before the dietary
deficiencies were recognized.
Another sometimes baffling complication is hypoglycemia
(32), a condition that may appear as long as 14 yr after the
surgery with plasma glucose levels as low as 30 mg%. Although
some recommend surgical intervention for this syndrome, all of
TABLE 2. SRC data from 272 ASMBS Centers of Excellence
with 495 surgeons reporting outcomes in more than 110,000
n %
Hospital mortality 76 0.14
Operative mortality at 30 d (76  89  165) 165 0.29
Operative mortality at 90 d (76  89  31  196) 196 0.35
Readmissions 1956 4.75
Reoperations 887 2.15
Data are based on applications.
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the 47 patients in our series recovered within 1 yr after conser-
vative approaches, ofwhich themost effectivewas the immediate
availability of hard candy when the patients felt an “aura” of an
oncoming attack.
The treatment of complications, both acute and long-term,
requires someone familiar with the uncommon and baffling syn-
dromes seen in the postbariatric surgical patient. Because some
of these adverse outcomes require very prompt action,measured
in hours, early consultation with a bariatric surgeon or a phy-
sician knowledgeable in this area is essential.
Summary
The best way to summarize the risks and benefits of bariatric
surgery is to present the data from a representative ASMBS Center
of Excellence, Dr. Robin Blackstone’s community practice, in
Scottsdale, Arizona, in Table 3. The preoperative status of the pa-
tients, the degree of resolution of the comorbidities, and the low
mortality rate (one patient 0.08%) provides a good index of the
quality of bariatric surgery delivered in the United States today.
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